Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2012

View Archived Issues

Novel small molecules target RNA binding site of human DDX3X

Telaprevir improves hepatitis C therapy in HIV-1-coinfected patients

Anti-fibrillogenic agents designed via out-of-plane substitutions show therapeutic potential

Studies demonstrate various therapeutic applications for SEH inhibition

Horizon Discovery and RFUMS to develop human cellular CF model

Recruitment complete in phase II BVT-115959 trial

Mologen seeks approval for study of MGN-1703 in NSCLC

OncoSec begins enrollment at two new sites for metastatic melanoma trial

New P2X4 receptor antagonist is active in models of neuropathic pain

Marina Biotech and ProNAi Therapeutics enter license agreement for DNAi-based therapies

New dipeptide calpain inhibitors reported by Banyan Biomarkers

Enanta presents novel candidate hepatitis C drugs

Novel p53-based peptidomimetics developed at Aileron Therapeutics

Shionogi & Co. divulges novel potential obesity drugs

Novel anti-infectives announced by Novacta Biosystems

Almirall attains new marketing rights to Sativex

Abbott begins phase III studies in hidradenitis suppurativa

Biogen Idec and MAKScientific enter MS agreement

Shire announces planned acquisition

Grifols acquires majority share in Araclon Biotech

Treatment begins in phase III study of CSL Behring's fibrinogen concentrate

Clinuvel provides update on phase III Scenesse trial

Aeras receives grant to develop new vaccines against TB

Thrombogenics and Alcon enter commercialization agreement for ocriplasmin

Novartis withdraws applications for new rivastigmine indication

Repligen commences first-in-human trial of HD inhibitor in Friedreich's ataxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...